Snyder, OK, United States

Oklahoma Medical Research Foundation

omrf.org
Snyder, OK, United States

The Oklahoma Medical Research Foundation , located in Oklahoma City, Oklahoma, is an independent, nonprofit biomedical research institute. Established in 1946, OMRF is dedicated to understanding and developing more effective treatments for human disease. Stephen M. Prescott, M.D., serves as president of OMRF, which employs more than 500 scientific and administrative staff members.OMRF’s scientists, who include a member of the National Academy of Sciences and a Howard Hughes Medical Institute investigator, hold more than 500 U.S. and international patents and have spun off 11 biotech companies. Discoveries at OMRF led to Xigris, the first FDA-approved drug for the treatment of severe sepsis, and Ceprotin, a therapy for people suffering from a rare and life-threatening blood disorder known as protein C deficiency. Research at OMRF also identified the enzyme believed responsible for Alzheimer’s disease and laid the groundwork for OncoVue, a breast cancer risk assessment test. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Oklahoma Medical Research Foundation | Date: 2017-01-31

The present invention includes a computerized method and non transitory computer readable medium that includes a code for determining errors within a text file in electronic format, the method comprising: obtaining an electronic file of the publication; identifying one or more possible errors in the electronic file using a processor; sorting the possible errors in the electronic file into one or more error categories; based on the error category, performing one or more of the following: (1) checking calculations on numerical errors, (2) checking an availability of cited external references, (3) statistical calculations, (4) determining consistent use of terminology, (5) checking nomenclature, or (6) identifying appropriate use of statistical tests; sorting possible errors into confirmed errors or corrected values for each possible error; and at least one of storing or displaying the confirmed errors.


Patent
Hough Ear Institute and Oklahoma Medical Research Foundation | Date: 2017-01-27

The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl -phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).


Patent
Hough Ear Institute and Oklahoma Medical Research Foundation | Date: 2017-04-24

The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl -phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.


Patent
Oklahoma Medical Research Foundation and University of Illinois at Urbana - Champaign | Date: 2017-06-28

Hypercoagulable and hyperinflammatory responses can lead to a variety of diseases including but not limited to disseminated intravascular coagulation in sepsis, consumptive coagulopathy in trauma, thrombosis in the postsurgical setting, acute respiratory distress syndrome in lung, and other diseases or conditions. Polyphosphate is accumulated by many infectious microorganisms and may be released by damaged infectious microorganisms. In addition, polyphosphate is found in many organs and is released from activated platelets and mast cells. Polyphosphates activate the intrinsic pathway of coagulation that also induces inflammation. Hypercoagulable and hyperinflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death, which occur in many pathological conditions. As such, polyphosphates can be targeted pharmacologically by inhibitors, such as anti-polyphosphate antibodies, as well as used as biomarkers for diagnosis, prognosis, and treatment response indicators that may be used to provide guidance for alterations in treatment plans.


Patent
Johns Hopkins University and Oklahoma Medical Research Foundation | Date: 2016-09-07

The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohns Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10.


Patent
Meso Scale Technologies LLC., Crescendo Bioscience and Oklahoma Medical Research Foundation | Date: 2016-11-29

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).


Patent
Oklahoma Medical Research Foundation | Date: 2016-10-13

The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.


Patent
Meso Scale Technologies LLC., Crescendo Bioscience and Oklahoma Medical Research Foundation | Date: 2016-12-22

Biomarkers useful for diagnosing and assessing inflammatory disease are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. The biomarkers include at least two biomarkers selected from the DAIMRK group and the score is a disease activity index (DAI).


HarmonicSS vision is to create an International Network and Alliance of partners and cohorts, entrusted with the mission of addressing the unmet needs in primary Sjogren Syndrome; working together to create and maintain a platform with open standards and tools, designed to enable secure storage, governance, analytics, access control and controlled sharing of information at multiple levels along with methods to make results of analyses and outcomes comparable across centers and sustainable through Rheumatology associations. The overall idea of the HarmonicSS project is to bring together the largest well characterized regional, national and international longitudinal cohorts of patients with Primary Sjgrens Syndrome (pSS) including those participating in clinical trials, and after taking into consideration the ethical, legal, privacy and IPR issues for sharing data from different countries, to semantically interlink and harmonize them into an integrative pSS cohort structure on the cloud. Upon this harmonized cohort, services for big data mining, governance and visual analytics will be integrated, to address the identified clinical and health policy pSS unmet needs. In addition, tools for specific diagnostic procedures (e.g. ultrasonography image segmentation), patient selection for clinical trials and training will be also provided. The users of the HarmonicSS platform are researchers (basic/translational), clinicians, health policy makers and pharma companies. pSS is relevant not only due to its clinical impact but also as one of the few model diseases to link autoimmunity, cancer development (lymphoproliferation) and the pathogenetic role of infection. Thus, the study of pSS can facilitate research in many areas of medicine; for this reason, the possibility for sustainability and expandability of the platform is enhanced. Moreover, pSS has a significant impact on the healthcare systems, similar to that of rheumatoid arthritis.


Sivakumar S.,Oklahoma Medical Research Foundation | Gorbsky G.J.,Oklahoma Medical Research Foundation
Nature Reviews Molecular Cell Biology | Year: 2015

The appropriate timing of events that lead to chromosome segregation during mitosis and cytokinesis is essential to prevent aneuploidy, and defects in these processes can contribute to tumorigenesis. Key mitotic regulators are controlled through ubiquitylation and proteasome-mediated degradation. The APC/C (anaphase-promoting complex; also known as the cyclosome) is an E3 ubiquitin ligase that has a crucial function in the regulation of the mitotic cell cycle, particularly at the onset of anaphase and during mitotic exit. Co-activator proteins, inhibitor proteins, protein kinases and phosphatases interact with the APC/C to temporally and spatially control its activity and thus ensure accurate timing of mitotic events. © 2015 Macmillan Publishers Limited. All rights reserved.

Loading Oklahoma Medical Research Foundation collaborators
Loading Oklahoma Medical Research Foundation collaborators